Medicare Part B Step Therapy Factor VIII Products
Customize your policy alerts
Sign up for zing_health Policy 5894-D alerts
Get alerted when Policy 5894-D changes without checking for updates manually.
Monitor payer policy activity
This policy governs Medicare Part B coverage and prior authorization for preferred and non-preferred recombinant Factor VIII products under an Advanced Biosimilars First step-therapy program. It applies to members who are new to treatment with a non-preferred product and establishes clinical exception pathways for non-preferred therapy.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.